1-5 of 5
Kensei Tobinai
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pooled analysis of pralatrexate single-agent studies in patients with relapsed/refractory peripheral T-cell lymphoma

Clinical Trials & Observations
Owen A. O’Connor, Bor-Sheng Ko, Ming-Chung Wang, Dai Maruyama, Yuqin Song, Ee-Min Yeoh, Nick Manamley, Kensei Tobinai
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2601–2611.
https://doi.org/10.1182/bloodadvances.2023010441
Published: 2024
Includes: Supplemental data
Journal Articles

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study

Clinical Trials & Observations
Won-Seog Kim, Noriko Fukuhara, Dok-Hyun Yoon, Kazuhito Yamamoto, Toshiki Uchida, Eiju Negoro, Koji Izutsu, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Hye Jin Kang, Po-Shen Ko, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Kensei Tobinai
Journal: Blood Advances
Blood Adv (2023) 7 (17): 4903–4912.
https://doi.org/10.1182/bloodadvances.2022008615
Published: 2023
Journal Articles

Role of stem cell transplant in CD30 + PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Clinical Trials & Observations
Kerry J. Savage, Steven M. Horwitz, Ranjana Advani, Jacob Haaber Christensen, Eva Domingo-Domenech, Giuseppe Rossi, Franck Morschhauser, Onder Alpdogan, Cheolwon Suh, Kensei Tobinai, Andrei Shustov, Marek Trneny, Sam Yuen, Pier Luigi Zinzani, Lorenz Trümper, Tim Ilidge, Owen A. O’Connor, Barbara Pro, Harry Miao, Veronica Bunn, Keenan Fenton, Michelle Fanale, Markus Puhlmann, Swaminathan Iyer
Journal: Blood Advances
Blood Adv (2022) 6 (19): 5550–5555.
https://doi.org/10.1182/bloodadvances.2020003971
Published: 2022
Includes: Supplemental data
Journal Articles

A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trial

Clinical Trials & Observations
Ken Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, Gakuto Ogawa, Tomonori Mizutani, Nobuhiko Yamauchi, Noriko Fukuhara, Toshiki Uchida, Kazuhito Yamamoto, Kana Miyazaki, Norifumi Tsukamoto, Shinsuke Iida, Takahiko Utsumi, Isao Yoshida, Yoshitaka Imaizumi, Takashi Tokunaga, Shinichiro Yoshida, Yasufumi Masaki, Tohru Murayama, Yoshihiro Yakushijin, Youko Suehiro, Kisato Nosaka, Nobuaki Dobashi, Junya Kuroda, Yasushi Takamatsu, Dai Maruyama, Kiyoshi Ando, Kenichi Ishizawa, Michinori Ogura, Tadashi Yoshino, Tomomitsu Hotta, Kunihiro Tsukasaki, Hirokazu Nagai, the Japan Clinical Oncology Group
Journal: Blood Advances
Blood Adv (2021) 5 (4): 984–993.
https://doi.org/10.1182/bloodadvances.2020002567
Published: 2021
Includes: Supplemental data
Journal Articles

A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy

Clinical Trials & Observations
David G. Maloney, Michinori Ogura, Noriko Fukuhara, Jaclyn Davis, Janet Lasher, Miguel Izquierdo, Hiya Banerjee, Kensei Tobinai
Journal: Blood Advances
Blood Adv (2020) 4 (16): 3886–3893.
https://doi.org/10.1182/bloodadvances.2020001942
Published: 2020